Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Articles

    AstraZeneca plc’s Not So Secret Weapon

    | Rupert Hargreaves

    AstraZeneca plc's (LON: AZN) CEO is committed to the company.

    Read more »

    Investing Articles

    This Thing Could Put A Rocket Under AstraZeneca plc’s Shares

    | G A Chester

    AstraZeneca plc (LON:AZN) has 35% potential upside.

    Read more »

    Investing Articles

    A New Bid For AstraZeneca plc In November?

    | Alan Oscroft

    Pfizer may be back for another tilt at AstraZenenca plc (LON: AZN).

    Read more »

    Investing Articles

    Should I Invest In AstraZeneca Plc Now?

    | Kevin Godbold

    Can AstraZeneca plc (LON: AZN) still deliver a decent investment return?

    Read more »

    Company Comment

    Is AstraZeneca plc A Buy On $45bn Revenue Targets?

    | Mark Stones

    Will AstraZeneca plc's (LON: AZN) drugs pipeline live up to expectations?

    Read more »

    Investing Articles

    Why Is AstraZeneca plc Still Trading At A Premium To GlaxoSmithKline plc?

    | Roland Head

    Roland Head asks why AstraZeneca plc (LON:AZN) continues to trade at a premium to GlaxoSmithKline plc (LON:GSK), following the failed…

    Read more »

    Investing Videos

    Neil Woodford Opens New Equity Income Fund

    | Owain Bennallack

    VIDEO: One Fool takes a look at Woodford's new fund.

    Read more »

    Company Comment

    17% Annual Growth For The Next 7 Years?

    | Maynard Paton

    Sadly, few quoted companies ever issue specific sales guidance...

    Read more »

    Investing Articles

    Why AstraZeneca plc Provides Poor Shareholder Value

    | Royston Wild

    Royston Wild looks at whether AstraZeneca plc (LON: AZN) is an attractive pick for value investors.

    Read more »

    Investing Articles

    AstraZeneca plc Shows The Danger Of Buying On Takeover Talk

    | Harvey Jones

    Traders may have lost, but investors should ultimately win from holding AstraZeneca plc (LON: AZN), says Harvey Jones.

    Read more »

    Investing Videos

    A Closer Look At AstraZeneca plc

    | Nate Weisshaar

    VIDEO: Two Fools put AstraZeneca plc (LON:AZN) under the spotlight.

    Read more »

    Investing Articles

    What’s Next For AstraZeneca plc?

    | Rupert Hargreaves

    Where will AstraZeneca plc (LON:AZN) go from here?

    Read more »